Key result
DOACs were associated with a similar incidence of ischemic stroke or TIA compared to warfarin in morbidly obese patients with atrial fibrillation or flutter (RR 0.84; 95% CI 0.23-3.14; P=0.80).
Why the study?
Do direct oral anticoagulants prevent ischemic stroke or TIA in morbidly obese patients with atrial fibrillation or flutter compared to warfarin?
Population
128 adults with morbid obesity and atrial fibrillation or flutter
Comparison
Direct oral anticoagulants vs Warfarin
Design
Cohort
Authors
Loading...
DOACs were associated with similar stroke/TIA rates versus warfarin in morbidly obese AF; hypothesis-generating and should not yet change practice.
Cohort (n=128)
No
Do direct oral anticoagulants prevent ischemic stroke or TIA in morbidly obese patients with atrial fibrillation or flutter compared to warfarin?
Relative Risk: 0.84 (95% CI 0.23–3.14)
Absolute Event Rate: 1.75% vs 2.07%
p-value: p=0.80
DOACs demonstrated comparable efficacy and safety to warfarin in morbidly obese patients with atrial fibrillation, suggesting they may be viable alternatives despite current guideline cautions.
Kido et al. (2018) conducted a cohort in Atrial fibrillation or flutter (n=128). DOACs vs. Warfarin was evaluated on Incidence of ischemic stroke or transient ischemic attack (TIA) (RR 0.84, 95% CI 0.23 to 3.14, p=0.80). DOACs were associated with a similar incidence of ischemic stroke or TIA compared to warfarin in morbidly obese patients with atrial fibrillation or flutter (RR 0.84; 95% CI 0.23-3.14; P=0.80).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: